TAE Life Sciences secures $30M in initial B round to accelerate development of unique boron delivery drugs for novel cancer treatment, boron neutron capture therapy (BNCT).
TAE Life Sciences (TLS), a biological-targeting radiation therapy company developing next-generation boron neutron capture therapy solutions (BNCT), announced the launch of an innovative in-house boron delivery drug development program supported by an influx of $30M in funding. The initial phase of the B-round funds comes from a consortium of investors including ARTIS Ventures, who led the company’s initial funding in 2018.